Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

Quesnelle KM, Grandis JR.

Clin Cancer Res. 2011 Sep 15;17(18):5935-44. doi: 10.1158/1078-0432.CCR-11-0370. Epub 2011 Jul 26.

PMID:
21791633
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.

Cancer Biol Ther. 2011 Sep 1;12(5):436-46. Epub 2011 Sep 1.

PMID:
21725209
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

PMID:
15701870
[PubMed - indexed for MEDLINE]
Free Article
4.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.

Neoplasia. 2012 Feb;14(2):121-30.

PMID:
22431920
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W.

Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5.

PMID:
22956644
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.

PMID:
22436374
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.

Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.

PMID:
23948973
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
9.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846. Epub 2012 Aug 1.

PMID:
22785204
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

PMID:
21961653
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.

Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.

Cancer Lett. 2010 Jun 1;292(1):54-63. doi: 10.1016/j.canlet.2009.11.004. Epub 2009 Dec 2.

PMID:
19959278
[PubMed - indexed for MEDLINE]
12.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
13.

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.

Int J Oncol. 2008 Dec;33(6):1165-76.

PMID:
19020749
[PubMed - indexed for MEDLINE]
14.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.

Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X.

Int J Oncol. 2009 Jan;34(1):25-32.

PMID:
19082474
[PubMed - indexed for MEDLINE]
15.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
[PubMed - indexed for MEDLINE]
16.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
17.

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M.

Cancer Res. 2005 Apr 15;65(8):3003-10.

PMID:
15833824
[PubMed - indexed for MEDLINE]
Free Article
18.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.

Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.

PMID:
22586653
[PubMed - indexed for MEDLINE]
19.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL.

Cancer Cell. 2006 Jul;10(1):25-38.

PMID:
16843263
[PubMed - indexed for MEDLINE]
Free Article
20.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk